Share This:
https://ntp.niehs.nih.gov/go/18441

TDMS Study 96021-01 Pathology Tables

NTP Experiment-Test: 96021-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: CHRONIC                           TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153)                       Date: 06/05/03
Route: GAVAGE                                                                                                     Time: 10:52:01

                                                      53 WEEK SSAC FINAL#1




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  35065-27-1

       Lock Date:  01/16/02

       Cage Range:  All

       Reasons For Removal:    25017 Scheduled Sacrifice

       Removal Date Range:     08/23/99 - 08/24/99

       Treatment Groups:       Include 001    0 UG/KG
                               Include 002    10 UG/KG
                               Include 003    100     UG/KG
                               Include 004    300     UG/KG
                               Include 005    1000    UG/KG
                               Include 006    3000    UG/KG





























a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 96021-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                           TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153)                       Date: 06/05/03    
Route: GAVAGE                                                                                                     Time: 10:52:01    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 UG/KG      10 UG/KG     100          300          1000         3000            
                                                                             UG/KG        UG/KG        UG/KG        UG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially In Study                          98           86           98           98           98           80           
                                                                                                                                    
  Scheduled Sacrifice                                 13           12           13           13           13            9           
  Early Deaths                                                                                                                      
  Survivors                                                                                                                         
                                                                                                                                    
  Animals Examined Microscopically                     8            8            8            8            8            9           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (8)          (8)          (8)          (8)          (8)          (9)          
      Basophilic Focus                                 1 (13%)      1 (13%)                                                         
      Clear Cell Focus                                 1 (13%)                                1 (13%)                               
      Eosinophilic Focus                               1 (13%)                   1 (13%)                                            
      Fatty Change, Diffuse                                                                                2 (25%)      1 (11%)     
      Hematopoietic Cell Proliferation                                           1 (13%)                                            
      Inflammation                                     7 (88%)      6 (75%)      8 (100%)     7 (88%)      8 (100%)     8 (89%)     
      Mixed Cell Focus                                 2 (25%)      2 (25%)      3 (38%)      1 (13%)      1 (13%)      2 (22%)     
      Mixed Cell Focus, Multiple                       4 (50%)      5 (63%)      1 (13%)      4 (50%)                               
      Bile Duct, Fibrosis                              1 (13%)                                                                      
      Hepatocyte, Hypertrophy                          1 (13%)                   3 (38%)      7 (88%)      8 (100%)     9 (100%)    
      Serosa, Pigmentation                                                                                 1 (13%)                  
   Stomach, Glandular                                 (8)                                                              (9)          
      Erosion                                          1 (13%)                                                                      
      Glands, Cyst                                                                                                      1 (11%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (8)                                                              (9)          
      Hyperplasia                                      1 (13%)                                                                      
      Hypertrophy                                      4 (50%)                                                          4 (44%)     
      Vacuolization Cytoplasmic                        1 (13%)                                                          1 (11%)     
   Pituitary Gland                                    (8)                                                              (9)          
      Cyst                                                                                                              1 (11%)     
   Thyroid Gland                                      (8)          (8)          (8)          (8)          (8)          (9)          
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    2                                                              
                                                                                                                                   
NTP Experiment-Test: 96021-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                           TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153)                       Date: 06/05/03    
Route: GAVAGE                                                                                                     Time: 10:52:01    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 UG/KG      10 UG/KG     100          300          1000         3000            
                                                                             UG/KG        UG/KG        UG/KG        UG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ENDOCRINE SYSTEM - CONT                                                                                                             
      C-Cell, Hyperplasia                              3 (38%)                                                          2 (22%)     
      Follicular Cell, Hypertrophy                     1 (13%)                   2 (25%)      1 (13%)      1 (13%)      3 (33%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                              (8)          (1)                       (1)          (1)          (9)          
      Atrophy                                          8 (100%)                                                         7 (78%)     
      Cyst                                             1 (13%)                                1 (100%)     1 (100%)                 
   Uterus                                             (8)                                                              (9)          
      Inflammation, Chronic Active                                                                                      1 (11%)     
      Inflammation, Suppurative                        2 (25%)                                                          1 (11%)     
      Metaplasia, Squamous                             5 (63%)                                                          6 (67%)     
      Endometrium, Hyperplasia, Cystic                 5 (63%)                                                          1 (11%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Lymph Node                                                      (1)                                                              
      Mediastinal, Hemorrhage                                       1 (100%)                                                        
      Mediastinal, Hyperplasia, Plasma Cell                         1 (100%)                                                        
   Spleen                                             (8)                                                              (9)          
      Hematopoietic Cell Proliferation                 1 (13%)                                                                      
      Pigmentation                                     7 (88%)                                                          9 (100%)    
   Thymus                                             (8)                                                              (9)          
      Atrophy                                          2 (25%)                                                          1 (11%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                                                                                                    
                                                             Page    3                                                              
                                                                                                                                   
NTP Experiment-Test: 96021-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                           TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153)                       Date: 06/05/03    
Route: GAVAGE                                                                                                     Time: 10:52:01    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 UG/KG      10 UG/KG     100          300          1000         3000            
                                                                             UG/KG        UG/KG        UG/KG        UG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (8)          (8)          (8)          (8)          (8)          (9)          
      Infiltration Cellular, Histiocyte                3 (38%)                                                          1 (11%)     
      Inflammation                                                                            1 (13%)                               
      Inflammation, Chronic                            1 (13%)                                                                      
      Alveolar Epithelium, Hyperplasia                              1 (13%)                   1 (13%)                               
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page    4                                                              
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------